Invesco LLC Sells 119 Shares of Humana Inc. (NYSE:HUM)

Invesco LLC lowered its stake in shares of Humana Inc. (NYSE:HUM) by 2.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,294 shares of the insurance provider’s stock after selling 119 shares during the period. Invesco LLC’s holdings in Humana were worth $1,089,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of HUM. Swedbank AB increased its position in Humana by 6.4% during the fourth quarter. Swedbank AB now owns 112,790 shares of the insurance provider’s stock worth $28,616,000 after acquiring an additional 6,814 shares during the period. Forsta AP Fonden increased its position in Humana by 2.0% during the 4th quarter. Forsta AP Fonden now owns 25,200 shares of the insurance provider’s stock worth $6,393,000 after purchasing an additional 500 shares in the last quarter. Asset Dedication LLC boosted its holdings in shares of Humana by 73.5% during the 4th quarter. Asset Dedication LLC now owns 800 shares of the insurance provider’s stock valued at $203,000 after acquiring an additional 339 shares in the last quarter. Matrix Asset Advisors Inc. NY bought a new stake in shares of Humana during the fourth quarter worth about $1,674,000. Finally, Revolve Wealth Partners LLC bought a new stake in Humana during the 4th quarter worth approximately $202,000. Institutional investors own 92.38% of the company’s stock.

Humana Stock Up 0.1 %

Shares of NYSE:HUM traded up $0.24 on Wednesday, reaching $303.35. The company had a trading volume of 140,454 shares, compared to its average volume of 1,490,794. The stock has a 50-day moving average price of $275.44 and a 200 day moving average price of $303.14. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $36.53 billion, a P/E ratio of 26.90, a P/E/G ratio of 2.15 and a beta of 0.55.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The business had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. On average, equities analysts expect that Humana Inc. will post 16.11 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on HUM shares. Barclays raised their price target on shares of Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 22nd. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research report on Thursday, October 3rd. Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price target for the company in a report on Tuesday, October 8th. Finally, Oppenheimer decreased their target price on Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research note on Thursday, October 3rd. Nineteen analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $297.68.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.